(ROVI) Laboratorios Farmaceuticos - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: MC (Spain) | Market Cap: 3.020m EUR | Total Return: 14% in 12m
Avg Turnover: 8.96M
EPS Trend: -78.5%
Rev. Trend: -91.0%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical company specializing in the development, manufacturing, and marketing of prescription drugs and hospital products. Its core portfolio includes low-molecular-weight heparins (LMWH), diagnostic imaging contrast agents, and treatments for the central nervous system, cardiology, and urology. The company operates a dual business model, combining proprietary drug sales with a significant contract manufacturing (CDMO) division that provides sterile filling and packaging services for global partners.
The pharmaceutical sector is characterized by high barriers to entry due to stringent regulatory requirements and the capital-intensive nature of sterile injectable production. Rovi’s CDMO segment benefits from this specialized infrastructure, offering end-to-end services from compounding to serialization for complex injectable forms like prefilled syringes. This diversification helps mitigate the risks associated with the patent lifecycles of individual proprietary medications.
To better understand the companys valuation and growth metrics, you may want to explore the data available on ValueRay. Founded in 1946 and headquartered in Pozuelo de Alarcón, Rovi maintains an international footprint across the European Union and OECD countries while remaining a subsidiary of Norbel Inversiones, S.L.
- Expansion of contract manufacturing capacity drives high-margin injectable revenue growth
- Global demand for low-molecular-weight heparin products dictates core pharmaceutical margins
- Success of long-acting injectable psychiatric drugs influences long-term valuation premiums
- Potential divestment or spin-off of manufacturing business impacts capital structure
- Regulatory approval timelines for Risperidone ISM determine future market share expansion
| Net Income: 131.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.56 > 1.0 |
| NWC/Revenue: 52.86% < 20% (prev 44.51%; Δ 8.35% < -1%) |
| CFO/TA 0.19 > 3% & CFO 180.6m > Net Income 131.8m |
| Net Debt (33.1m) to EBITDA (200.0m): 0.17 < 3 |
| Current Ratio: 3.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago 0.01% < -2% |
| Gross Margin: 63.23% > 18% (prev 0.62%; Δ 6.26k% > 0.5%) |
| Asset Turnover: 85.17% > 50% (prev 94.29%; Δ -9.12% > 0%) |
| Interest Coverage Ratio: 56.27 > 6 (EBITDA TTM 200.0m / Interest Expense TTM 3.00m) |
| A: 0.42 (Total Current Assets 539.3m - Total Current Liabilities 147.5m) / Total Assets 926.3m |
| B: 0.64 (Retained Earnings 589.3m / Total Assets 926.3m) |
| C: 0.19 (EBIT TTM 168.7m / Avg Total Assets 870.1m) |
| D: 2.48 (Book Value of Equity 593.0m / Total Liabilities 239.6m) |
| Altman-Z'' = 8.75 = AAA |
| DSRI: 1.46 (Receivables 164.3m/116.2m, Revenue 741.1m/767.5m) |
| GMI: 0.97 (GM 63.23% / 61.56%) |
| AQI: 0.88 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 0.97 (Revenue 741.1m / 767.5m) |
| TATA: -0.05 (NI 131.8m - CFO 180.6m) / TA 926.3m) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at EUR 59.30 with a total of 170,346 shares traded.
Over the past week, the price has changed by +0.42%,
over one month by -24.60%,
over three months by -30.03% and
over the past year by +13.97%.
Laboratorios Farmaceuticos has no consensus analysts rating.
P/E Trailing = 25.0212
P/E Forward = 36.63
P/S = 4.0625
P/B = 4.4819
P/EG = 1.2569
Revenue TTM = 741.1m EUR
EBIT TTM = 168.7m EUR
EBITDA TTM = 200.0m EUR
Long Term Debt = 86.7m EUR (estimated: total debt 114.4m - short term 27.8m)
Short Term Debt = 27.8m EUR (from shortTermDebt, last quarter)
Debt = 130.5m EUR (from shortLongTermDebtTotal, last quarter) + Leases 16.1m
Net Debt = 33.1m EUR (calculated: Debt 130.5m - CCE 97.4m)
Enterprise Value = 3.05b EUR (3.02b + Debt 130.5m - CCE 97.4m)
Interest Coverage Ratio = 56.27 (Ebit TTM 168.7m / Interest Expense TTM 3.00m)
EV/FCF = 26.59x (Enterprise Value 3.05b / FCF TTM 114.8m)
FCF Yield = 3.76% (FCF TTM 114.8m / Enterprise Value 3.05b)
FCF Margin = 15.49% (FCF TTM 114.8m / Revenue TTM 741.1m)
Net Margin = 17.79% (Net Income TTM 131.8m / Revenue TTM 741.1m)
Gross Margin = 63.23% ((Revenue TTM 741.1m - Cost of Revenue TTM 272.5m) / Revenue TTM)
Gross Margin QoQ = 55.56% (prev 59.87%)
Tobins Q-Ratio = 3.30 (Enterprise Value 3.05b / Total Assets 926.3m)
Interest Expense / Debt = 2.30% (Interest Expense 3.00m / Debt 130.5m)
Taxrate = 23.11% (2.84m / 12.3m)
NOPAT = 129.7m (EBIT 168.7m * (1 - 23.11%))
Current Ratio = 3.66 (Total Current Assets 539.3m / Total Current Liabilities 147.5m)
Debt / Equity = 0.19 (Debt 130.5m / totalStockholderEquity, last quarter 673.9m)
Debt / EBITDA = 0.17 (Net Debt 33.1m / EBITDA 200.0m)
Debt / FCF = 0.29 (Net Debt 33.1m / FCF TTM 114.8m)
Total Stockholder Equity = 630.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.15% (Net Income 131.8m / Total Assets 926.3m)
RoE = 20.89% (Net Income TTM 131.8m / Total Stockholder Equity 630.9m)
RoCE = 23.52% (EBIT 168.7m / Capital Employed (Equity 630.9m + L.T.Debt 86.7m))
RoIC = 18.30% (NOPAT 129.7m / Invested Capital 709.2m)
WACC = 6.91% (E(3.02b)/V(3.15b) * Re(7.13%) + D(130.5m)/V(3.15b) * Rd(2.30%) * (1-Tc(0.23)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -29.02 | Cagr: -0.58%
[DCF] Terminal Value 77.97% ; FCFF base≈100.9m ; Y1≈115.7m ; Y5≈170.3m
[DCF] Fair Price = 49.45 (EV 2.56b - Net Debt 33.1m = Equity 2.53b / Shares 51.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -78.53 | EPS CAGR: -11.24% | SUE: N/A | # QB: 0
Revenue Correlation: -91.04 | Revenue CAGR: -4.63% | SUE: 0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=2.56 | Chg30d=-16.68% | Revisions=-40% | GrowthEPS=-7.0% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=3.58 | Chg30d=-17.00% | Revisions=-40% | GrowthEPS=+39.9% | GrowthRev=+18.0%
[Analyst] Revisions Ratio: -40%